Trial reportRespiratory research2005
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.
Trial report in Respiratory research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.Advances in rheumatology (London, England) · 2022Pooled it
- Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.International journal of chronic obstructive pulmonary disease · 2017Trial
- Unraveling the Underlying Molecular Mechanism of 'Silent Hypoxia' in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway.Journal of clinical medicine · 2023Review
- The impact of COVID-19 on populations living at high altitude: Role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication.Frontiers in physiology · 2022Article
- Treatment of pulmonary hypertension associated with COPD: a systematic review.ERJ open research · 2022Article
- Neurohormonal modulation in pulmonary arterial hypertension.The European respiratory journal · 2021Review
- Pulmonary hypertension: Pathophysiology beyond the lung.Pharmacological research · 2020Review
- ACE and response to pulmonary rehabilitation in COPD: two observational studies.BMJ open respiratory research · 2017Article
- Molecular and cellular mechanisms of the inhibitory effects of ACE-2/ANG1-7/Mas axis on lung injury.Current topics in pharmacology · 2014Article
- The role of local renin-angiotensin system in arterial chemoreceptors in sleep-breathing disorders.Frontiers in physiology · 2014Review
- The renin-angiotensin system in pulmonary hypertension.American journal of respiratory and critical care medicine · 2013Article
- Article
- Pulmonary Hypertension Secondary to COPD.Pulmonary medicine · 2012Article
- Review
- Pulmonary hypertension associated with COPD.International journal of chronic obstructive pulmonary disease · 2008Review
- Angiotensin-converting enzyme 2 in lung diseases.Current opinion in pharmacology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMorbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur. Whether chronic angiotensin-II blockade is beneficial is unknown. We studied the effects of an angiotensin-II antagonist losartan, on haemodynamic variables, exercise capacity and symptoms.
methodsThis was a double-blind, randomized, parallel group, placebo- controlled study of 48 weeks duration. Forty patients with COPD and pulmonary hypertension (Tran tricuspid pressure gradient (TTPG) = 30 mmHg) were randomised to losartan 50 mg or placebo. Changes in TTPG were assessed at 3, 6 and 12 months.
resultsThere was a trend for TTPG to increase in the placebo group (baseline 43.4 versus 48.4 mmHg at endpoint) and stay constant in the losartan group (baseline 42.8 versus 43.6 mmHg). More patients in the losartan group (50%) than in the placebo group (22%) showed a clinically meaningful reduction in TTPG at any timepoint; these effects seemed more marked in patients with higher baseline TTPG. There were no clear improvements in exercise capacity or symptoms.
conclusionIn this 12-month pilot study, losartan 50 mg had no statistically significant beneficial effect on TTPG, exercise capacity or symptoms in pulmonary hypertension secondary to obstructive disease. A sub-group of patients with higher TTPG may benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.